New Delhi, Aug. 5 -- Hyderabad-based Natco Pharma has once again moved the Delhi High Court against the Indian Patent Office's decision to grant a patent for the breast cancer drug ribociclib (Kisqali) to Swiss drugmaker Novartis AG and UK-based Astex Therapeutics.

Justice Anup Jairam Bhambhani briefly heard the matter on Wednesday, issued notice to all parties, and listed the case for further hearing on 16 September.

In a petition reviewed by Mint, Natco argued that the fresh patent would unfairly extend Novartis's monopoly over the medicine. The drugmaker challenged the patent office's order dated 10 July 2026, which rejected four pre-grant oppositions and directed the grant of the ribociclib patent with a single amended claim. The pa...